Medistim utilizes several business models to effectively reach different segments of the US market.
In addition to traditional capital investments and purchase of consumables, hospitals can choose to enter leasing agreements or Pay Per Procedure (PPP). The PPP functionality has proven to be a popular option with our previous generation of medical device (VeriQ^TM and VeriQC^TM) and will now also be available to our MiraQ customers.

“Some of our largest customers in the USA are greatly appreciating the PPP model with their current VeriQ^TM and Medistim wants to make their transition to the latest platform MiraQ^TM as smooth as possible,” says Medistim President and CEO, Kari E. Krogstad. “The US market is key to Medistim’s success, making up about 1/3 of the global potential market, and it is our priority to respond to our customers’ preferences.”

For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com